Sökning: "TKI discontinuation"

Hittade 3 avhandlingar innehållade orden TKI discontinuation.

  1. 1. Clinical and Immunological Studies in Chronic Myeloid Leukaemia

    Författare :Stina Söderlund; Ulla Olsson-Strömberg; Angelica Loskog; Satu Mustjoki; Dragana Milojkovic; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; chronic myeloid leukaemia; accelerated phase; blast crisis; tyrosine kinase inhibitor; immunology; myeloid-derived suppressor cells; cytokines; proteomics; TKI discontinuation; population-based;

    Sammanfattning : Chronic myeloid leukaemia (CML) is characterised by the constitutively active tyrosine kinase BCR-ABL. Standard treatment with tyrosine kinase inhibitors (TKI) in the chronic phase (CP) of CML conveys excellent long-term prognosis but is associated with side effects and costs. LÄS MER

  3. 2. Clinical and Genetic studies in Chronic Myeloid Leukaemia

    Författare :Hjalmar Flygt; Ulla Olsson Strömberg; Stina Söderlund; Lucia Cavelier; Jane Apperley; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Haematology; Chronic Myeloid Leukemia; Medicinsk vetenskap; Medical Science;

    Sammanfattning : This thesis explores strategies to enhance deep molecular response (DMR) rates and treatment-free remission (TFR) eligibility in chronic myeloid leukaemia (CML), investigates factors linked to treatment milestone failures, describes tyrosine kinase inhibitor (TKI) discontinuation outcomes in a population-based cohort, and examines TFR probabilities after a second TKI discontinuation. In paper I we examined data from the Swedish CML registry on 128 CML patients in chronic phase with a reported TKI discontinuation of ≥1 month due to DMR. LÄS MER

  4. 3. Chronic myeloid leukemia-clinical, experimental and health economic studies with special reference to imatinib treatment

    Författare :Lotta Ohm; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting hematopoiesis, particularly resulting in increased numbers of white blood cells in the peripheral blood. LÄS MER